Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly vs metformin, sitagliptin, and pioglitazone in drug-naive type 2 diabetes
2008-000854-11Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of exenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to week 26. Started Jun 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-000854-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000854-11.